What did Dr. Pedersen discover about GS-441524 and feline FIP?
Dr. Niels Pedersen demonstrated in 2019 that the antiviral GS-441524 could reverse the clinical signs of Feline Infectious Peritonitis (FIP) in most treated cats. In his study, the animals received daily injections for 12 weeks and, in the cases that completed treatment, the survival rate was 100%. This finding marked a before and after in the treatment of a disease previously considered fatal.
A turning point for FIP
Until very recently, Feline Infectious Peritonitis (FIP) was practically a death sentence. Owners received a devastating diagnosis knowing that the life expectancy after confirmation was just a few days or weeks.
All of this changed in September 2019, when the renowned Dr. Niels Pedersen and his team published a study that marked a turning point: the efficacy of GS-441524, an antiviral capable of saving the lives of cats with FIP.
(If you want to know the technical details, complete data and methodology of the original study, see our FIP studies and research.)
The study that lit the light of hope
Dr. Pedersen’s work treated cats with different types of FIP: effusive, non-effusive, ocular and even neurological forms — the latter being especially complex.
Treatment consisted of daily injections for 12 weeks. The results were remarkable:
- Most of the treated cats completed therapy successfully.
- Those with ocular or neurological FIP required higher doses.
- No cat that finished treatment died during follow-up.
This was the first major scientific backing for a treatment that, until then, was almost unknown outside specialist circles.
Spain and the first relapse protocol
Although the study was published in the United States, in Spain there were already owners and vets using GS-441524 experimentally.
One of the most inspiring cases was that of an owner who, after his cat relapsed, decided to write directly to Dr. Pedersen. With the collaboration of a feline vet in Madrid, from that experience came the world’s first protocol for treating relapses.
That cat is still alive today, and his story is a reminder that perseverance and science can save lives.
What came next
Following Pedersen’s study, research and documented cases have multiplied, including clinical series in Spain with dozens of treated cats and a cure rate above 75%.
If you want to know real data on the scientific evidence accumulated since 2019, visit our section on FIP research.
FIP types in Dr. Pedersen’s study
The study included cats with different clinical presentations. This was the distribution by type:
| FIP type | Distribution in the study |
|---|---|
| Abdominal effusion | 33% |
| Non-effusive (dry) | 22% |
| Ocular | 19% |
| Pleural effusion | 4% |
| Neurological | 4% |
The neurological forms, although the most complex, also responded to treatment with higher doses — a key finding that opened the door to treating one of the most devastating types of FIP.
FIP types and current treatment options
Today we know that FIP can present in different clinical forms:
- Effusive (abdominal or pleural)
- Non-effusive (dry)
- Ocular
- Neurological
Each requires specific management and dosing. You can learn to recognise them and understand their diagnosis in our FIP diagnosis and types guide.
And if you are looking for information on protocols, doses and monitoring, we recommend consulting our FIP treatments page.
Frequently asked questions about Pedersen’s study and GS-441524
Why was Pedersen’s study so important for FIP?
Because it was the first to demonstrate, with published and peer-reviewed data, that an antiviral could reverse the disease in cats who until then had a fatal prognosis.
When was the study on GS-441524 published?
The study was published in September 2019 and has since inspired multiple investigations and clinical cases worldwide.
What was different about this study compared to earlier attempts?
Whereas previous treatments were purely palliative, GS-441524 showed the ability to eliminate clinical signs and achieve full recovery in many cases.
How did GS-441524 come to be used in Spain?
Through pioneering cases of owners and vets who adapted international experience and, in some cases, developed their own protocols for managing relapses — including the first relapse protocol born in Spain from direct contact with Dr. Pedersen.
What impact did this discovery have on the feline community?
It generated a global network of owners and vets sharing protocols, results and success stories, radically changing the way FIP is understood and confronted.
Has your cat beaten FIP thanks to GS-441524? Share your story to give hope to other owners who are starting this journey. Every testimony helps more people learn that today, FIP is no longer synonymous with the end.